. 2014; 22(3): 111-116 | |||
Therapeutic evaluation of Kalonji (Nigella sativa) in dyslipidemia - A randomized control trialAbdur Rasheed1, M. A. Siddiqui2, Javed A. Khan31Department of Moaljat, Abdul Ali Tibbiya College, Katoli.2National Institute of Unani Medicine, Bangalore. 3Department of Moalajat, National Institute of Unani Medicine, Bangalore. Dyslipidemia is one of the most common risk factors of cardiovascular diseases. An increased level of cholesterol is responsible for atherogenesis, which ultimately leads to the development of cardiovascular, cerebrovascular, and peripheral vascular diseases. According to a survey report, 36.3% patients are dyslipidemic; therefore, the problem is increasing day by day as a huge cause of morbidity and carries economic burden for society. These days, dyslipidemia is treated using lipid-lowering agents with lifestyle intervention; however, lipid-lowering agents produce various side effects. In Unani system of medicine, several drugs are used as lipid-lowering agents, which are comparatively safe. However, such drugs are still not validated on scientific parameters. Thus, a clinical trial was conducted with the objective to evaluate the efficacy and safety of Unani drugs in the management of dyslipidemia. Abdur Rasheed, M. A. Siddiqui, Javed A. Khan. Therapeutic evaluation of Kalonji (Nigella sativa) in dyslipidemia - A randomized control trial. . 2014; 22(3): 111-116 Sorumlu Yazar: Javed A. Khan, India |
|